Neuropathic Pain - Pipeline Review, H2 2016

Date: December 28, 2016
Pages: 561
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N8DC6078A19EN
Leaflet:

Download PDF Leaflet

Neuropathic Pain - Pipeline Review, H2 2016
Neuropathic Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain – Pipeline Review, H2 2016, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 6, 27, 29, 1, 119, 21 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 1 molecules, respectively.

Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Neuropathic Pain Overview
Therapeutics Development
Neuropathic Pain - Therapeutics under Development by Companies
Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes
Neuropathic Pain - Pipeline Products Glance
Neuropathic Pain - Products under Development by Companies
Neuropathic Pain - Products under Investigation by Universities/Institutes
Neuropathic Pain - Companies Involved in Therapeutics Development
Neuropathic Pain - Therapeutics Assessment
Drug Profiles
Neuropathic Pain - Dormant Projects
Neuropathic Pain - Discontinued Products
Neuropathic Pain - Product Development Milestones
Appendix 534

LIST OF TABLES

Number of Products under Development for Neuropathic Pain, H2 2016
Number of Products under Development for Neuropathic Pain - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Neuropathic Pain - Pipeline by 2-BBB Medicines BV, H2 2016
Neuropathic Pain - Pipeline by AbbVie Inc, H2 2016
Neuropathic Pain - Pipeline by Acadia Pharmaceuticals Inc, H2 2016
Neuropathic Pain - Pipeline by Achelios Therapeutics Inc, H2 2016
Neuropathic Pain - Pipeline by Adynxx Inc, H2 2016
Neuropathic Pain - Pipeline by Aevi Genomic Medicine Inc, H2 2016
Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H2 2016
Neuropathic Pain - Pipeline by Amura Holdings Ltd, H2 2016
Neuropathic Pain - Pipeline by AnaBios Corp, H2 2016
Neuropathic Pain - Pipeline by Anavex Life Sciences Corp, H2 2016
Neuropathic Pain - Pipeline by AngioChem Inc, H2 2016
Neuropathic Pain - Pipeline by APT Therapeutics Inc, H2 2016
Neuropathic Pain - Pipeline by Aquilus Pharmaceuticals Inc, H2 2016
Neuropathic Pain - Pipeline by Araim Pharmaceuticals Inc, H2 2016
Neuropathic Pain - Pipeline by Arena Pharmaceuticals Inc, H2 2016
Neuropathic Pain - Pipeline by Asahi Kasei Pharma Corp, H2 2016
Neuropathic Pain - Pipeline by Astellas Pharma Inc, H2 2016
Neuropathic Pain - Pipeline by AstraZeneca Plc, H2 2016
Neuropathic Pain - Pipeline by BCI Pharma, H2 2016
Neuropathic Pain - Pipeline by Biogen Inc, H2 2016
Neuropathic Pain - Pipeline by BioLineRx Ltd, H2 2016
Neuropathic Pain - Pipeline by Biomar Microbial Technologies, H2 2016
Neuropathic Pain - Pipeline by Bionomics Ltd, H2 2016
Neuropathic Pain - Pipeline by Bristol-Myers Squibb Company, H2 2016
Neuropathic Pain - Pipeline by Can-Fite BioPharma Ltd, H2 2016
Neuropathic Pain - Pipeline by Cara Therapeutics Inc, H2 2016
Neuropathic Pain - Pipeline by Catalyst Biosciences Inc, H2 2016
Neuropathic Pain - Pipeline by Cavion LLC, H2 2016
Neuropathic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016
Neuropathic Pain - Pipeline by Cerecor Inc, H2 2016
Neuropathic Pain - Pipeline by Chromocell Corp, H2 2016
Neuropathic Pain - Pipeline by Circuit Therapeutics Inc, H2 2016
Neuropathic Pain - Pipeline by CLL Pharma SA, H2 2016
Neuropathic Pain - Pipeline by Colby Pharmaceutical Company, H2 2016
Neuropathic Pain - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016
Neuropathic Pain - Pipeline by Crinetics Pharmaceuticals Inc, H2 2016
Neuropathic Pain - Pipeline by Cytogel Pharma LLC, H2 2016
Neuropathic Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016
Neuropathic Pain - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
Neuropathic Pain - Pipeline by Develco Pharma Schweiz AG, H2 2016
Neuropathic Pain - Pipeline by Dompe Farmaceutici SpA, H2 2016
Neuropathic Pain - Pipeline by Eisai Co Ltd, H2 2016
Neuropathic Pain - Pipeline by Eli Lilly and Company, H2 2016
Neuropathic Pain - Pipeline by Endece LLC, H2 2016
Neuropathic Pain - Pipeline by Evec Inc, H2 2016
Neuropathic Pain - Pipeline by Genecode AS, H2 2016
Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016
Neuropathic Pain - Pipeline by Glialogix Inc, H2 2016
Neuropathic Pain - Pipeline by Grunenthal GmbH, H2 2016
Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016
Neuropathic Pain - Pipeline by Hydra Biosciences Inc, H2 2016
Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc, H2 2016
Neuropathic Pain - Pipeline by Inpellis Inc, H2 2016
Neuropathic Pain - Pipeline by Integral Molecular Inc, H2 2016
Neuropathic Pain - Pipeline by Intellipharmaceutics International Inc, H2 2016
Neuropathic Pain - Pipeline by iX Biopharma Ltd, H2 2016
Neuropathic Pain - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016
Neuropathic Pain - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016
Neuropathic Pain - Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H2 2016
Neuropathic Pain - Pipeline by Johnson & Johnson, H2 2016
Neuropathic Pain - Pipeline by Kareus Therapeutics SA, H2 2016
Neuropathic Pain - Pipeline by Knopp Biosciences LLC, H2 2016
Neuropathic Pain - Pipeline by Kolon Life Science Inc, H2 2016
Neuropathic Pain - Pipeline by KPI Therapeutics Inc, H2 2016
Neuropathic Pain - Pipeline by Laboratorios Del Dr Esteve SA, H2 2016
Neuropathic Pain - Pipeline by Lexicon Pharmaceuticals Inc, H2 2016
Neuropathic Pain - Pipeline by Lohocla Research Corp, H2 2016
Neuropathic Pain - Pipeline by Lpath Inc, H2 2016
Neuropathic Pain - Pipeline by Mapi Pharma Ltd, H2 2016
Neuropathic Pain - Pipeline by Medestea Research & Production SpA, H2 2016
Neuropathic Pain - Pipeline by Medifron DBT Co Ltd, H2 2016
Neuropathic Pain - Pipeline by Medisyn Technologies Inc, H2 2016
Neuropathic Pain - Pipeline by Medy-Tox Inc, H2 2016
Neuropathic Pain - Pipeline by Merck & Co Inc, H2 2016
Neuropathic Pain - Pipeline by Nanomerics Ltd, H2 2016
Neuropathic Pain - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016
Neuropathic Pain - Pipeline by Neurocentrx Pharma Ltd, H2 2016
Neuropathic Pain - Pipeline by NeuroCycle Therapeutics GmbH, H2 2016
Neuropathic Pain - Pipeline by NeuroMax, H2 2016
Neuropathic Pain - Pipeline by NeurOp Inc, H2 2016
Neuropathic Pain - Pipeline by Newron Pharmaceuticals SpA, H2 2016
Neuropathic Pain - Pipeline by Nippon Chemiphar Co Ltd, H2 2016
Neuropathic Pain - Pipeline by NoNO Inc, H2 2016
Neuropathic Pain - Pipeline by Novaremed Ltd, H2 2016
Neuropathic Pain - Pipeline by Novartis AG, H2 2016
Neuropathic Pain - Pipeline by NsGene A/S, H2 2016
Neuropathic Pain - Pipeline by Omeros Corp, H2 2016
Neuropathic Pain - Pipeline by Orion Oyj, H2 2016
Neuropathic Pain - Pipeline by Patagonia Pharmaceuticals LLC, H2 2016
Neuropathic Pain - Pipeline by PeriphaGen Inc, H2 2016
Neuropathic Pain - Pipeline by Pfizer Inc, H2 2016
Neuropathic Pain - Pipeline by Pharmaleads SA, H2 2016
Neuropathic Pain - Pipeline by PharmEste Srl, H2 2016
Neuropathic Pain - Pipeline by Phosphagenics Ltd, H2 2016
Neuropathic Pain - Pipeline by Prismic Pharmaceuticals Inc, H2 2016
Neuropathic Pain - Pipeline by RaQualia Pharma Inc, H2 2016
Neuropathic Pain - Pipeline by Re-Pharm Ltd, H2 2016
Neuropathic Pain - Pipeline by Relmada Therapeutics Inc, H2 2016
Neuropathic Pain - Pipeline by Revance Therapeutics Inc, H2 2016
Neuropathic Pain - Pipeline by Saniona AB, H2 2016
Neuropathic Pain - Pipeline by Scilex Pharmaceuticals Inc, H2 2016
Neuropathic Pain - Pipeline by Shionogi & Co Ltd, H2 2016
Neuropathic Pain - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016
Neuropathic Pain - Pipeline by Sphaera Pharma Pvt Ltd, H2 2016
Neuropathic Pain - Pipeline by Spherium Biomed SL, H2 2016
Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc, H2 2016
Neuropathic Pain - Pipeline by Syntrix Biosystems Inc, H2 2016
Neuropathic Pain - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
Neuropathic Pain - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016
Neuropathic Pain - Pipeline by Theranexus SAS, H2 2016
Neuropathic Pain - Pipeline by Theravasc Inc, H2 2016
Neuropathic Pain - Pipeline by Toray Industries Inc, H2 2016
Neuropathic Pain - Pipeline by Torrent Pharmaceuticals Ltd, H2 2016
Neuropathic Pain - Pipeline by Trevena Inc, H2 2016
Neuropathic Pain - Pipeline by Trigemina Inc, H2 2016
Neuropathic Pain - Pipeline by Virobay Inc, H2 2016
Neuropathic Pain - Pipeline by VistaGen Therapeutics Inc, H2 2016
Neuropathic Pain - Pipeline by Vitality Biopharma Inc, H2 2016
Neuropathic Pain - Pipeline by Yuhan Corp, H2 2016
Neuropathic Pain - Pipeline by Yungjin Pharm Co Ltd, H2 2016
Neuropathic Pain - Pipeline by Zynerba Pharmaceuticals Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Neuropathic Pain - Dormant Projects, H2 2016
Neuropathic Pain - Dormant Projects (Contd..1), H2 2016
Neuropathic Pain - Dormant Projects (Contd..2), H2 2016
Neuropathic Pain - Dormant Projects (Contd..3), H2 2016
Neuropathic Pain - Dormant Projects (Contd..4), H2 2016
Neuropathic Pain - Dormant Projects (Contd..5), H2 2016
Neuropathic Pain - Dormant Projects (Contd..6), H2 2016
Neuropathic Pain - Dormant Projects (Contd..7), H2 2016
Neuropathic Pain - Dormant Projects (Contd..8), H2 2016
Neuropathic Pain - Dormant Projects (Contd..9), H2 2016
Neuropathic Pain - Dormant Projects (Contd..10), H2 2016
Neuropathic Pain - Dormant Projects (Contd..11), H2 2016
Neuropathic Pain - Dormant Projects (Contd..12), H2 2016
Neuropathic Pain - Dormant Projects (Contd..13), H2 2016
Neuropathic Pain - Dormant Projects (Contd..14), H2 2016
Neuropathic Pain - Dormant Projects (Contd..15), H2 2016
Neuropathic Pain - Dormant Projects (Contd..16), H2 2016
Neuropathic Pain - Dormant Projects (Contd..17), H2 2016
Neuropathic Pain - Dormant Projects (Contd..18), H2 2016
Neuropathic Pain - Dormant Projects (Contd..19), H2 2016
Neuropathic Pain - Dormant Projects (Contd..20), H2 2016
Neuropathic Pain - Dormant Projects (Contd..21), H2 2016
Neuropathic Pain - Dormant Projects (Contd..22), H2 2016
Neuropathic Pain - Dormant Projects (Contd..23), H2 2016
Neuropathic Pain - Dormant Projects (Contd..24), H2 2016
Neuropathic Pain - Discontinued Products, H2 2016
Neuropathic Pain - Discontinued Products (Contd..1), H2 2016
Neuropathic Pain - Discontinued Products (Contd..2), H2 2016
Neuropathic Pain - Discontinued Products (Contd..3), H2 2016
Neuropathic Pain - Discontinued Products (Contd..4), H2 2016
Neuropathic Pain - Discontinued Products (Contd..5), H2 2016
Neuropathic Pain - Discontinued Products (Contd..6), H2 2016
Neuropathic Pain - Discontinued Products (Contd..7), H2 2016 549

LIST OF FIGURES

Number of Products under Development for Neuropathic Pain, H2 2016
Number of Products under Development for Neuropathic Pain - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Visceral Pain - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 58 pages
Visceral Pain - Pipeline Review, H1 2017 US$ 2,000.00 Mar, 2017 · 56 pages
Ocular Pain - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 70 pages

Ask Your Question

Neuropathic Pain - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: